CN106913533A - 基于聚(dl‑乳酸‑乙醇酸共聚物)的用于光动力疗法的纳米粒子载体系统 - Google Patents

基于聚(dl‑乳酸‑乙醇酸共聚物)的用于光动力疗法的纳米粒子载体系统 Download PDF

Info

Publication number
CN106913533A
CN106913533A CN201710128404.2A CN201710128404A CN106913533A CN 106913533 A CN106913533 A CN 106913533A CN 201710128404 A CN201710128404 A CN 201710128404A CN 106913533 A CN106913533 A CN 106913533A
Authority
CN
China
Prior art keywords
nano
particle
nanoparticles
pharmaceutical preparation
plga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710128404.2A
Other languages
English (en)
Chinese (zh)
Inventor
克劳斯·兰格尔
托马斯·克诺布洛赫
比特·罗德
安格莱特·普鲁斯
沃科尔·阿尔布莱奇特
苏珊娜·格拉菲
阿诺·维厄
哈根·冯布里森
卡林·洛
西尔维娅·瓦格内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec Investment Ii Co Ltd
Biolitec Inc
Original Assignee
Biolitec Investment Ii Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolitec Investment Ii Co Ltd filed Critical Biolitec Investment Ii Co Ltd
Publication of CN106913533A publication Critical patent/CN106913533A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710128404.2A 2009-12-11 2010-12-08 基于聚(dl‑乳酸‑乙醇酸共聚物)的用于光动力疗法的纳米粒子载体系统 Pending CN106913533A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28589509P 2009-12-11 2009-12-11
US61/285,895 2009-12-11
US12/941,447 2010-11-08
US12/941,447 US20110275686A1 (en) 2009-12-11 2010-11-08 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
CN2010800629259A CN102740892A (zh) 2009-12-11 2010-12-08 基于聚(dl-乳酸-乙醇酸共聚物)（plga）的用于光动力疗法（pdt）的纳米粒子载体系统

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800629259A Division CN102740892A (zh) 2009-12-11 2010-12-08 基于聚(dl-乳酸-乙醇酸共聚物)（plga）的用于光动力疗法（pdt）的纳米粒子载体系统

Publications (1)

Publication Number Publication Date
CN106913533A true CN106913533A (zh) 2017-07-04

Family

ID=44146154

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710128404.2A Pending CN106913533A (zh) 2009-12-11 2010-12-08 基于聚(dl‑乳酸‑乙醇酸共聚物)的用于光动力疗法的纳米粒子载体系统
CN2010800629259A Pending CN102740892A (zh) 2009-12-11 2010-12-08 基于聚(dl-乳酸-乙醇酸共聚物)（plga）的用于光动力疗法（pdt）的纳米粒子载体系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800629259A Pending CN102740892A (zh) 2009-12-11 2010-12-08 基于聚(dl-乳酸-乙醇酸共聚物)（plga）的用于光动力疗法（pdt）的纳米粒子载体系统

Country Status (7)

Country Link
US (1) US20110275686A1 (enExample)
EP (1) EP2509633B1 (enExample)
JP (1) JP5868869B2 (enExample)
CN (2) CN106913533A (enExample)
BR (1) BR112012013951A2 (enExample)
CA (1) CA2784005C (enExample)
WO (1) WO2011071970A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111000804A (zh) * 2019-12-05 2020-04-14 东南大学 一种甘露糖靶向的热响应铂纳米颗粒及其制备方法和应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211283B2 (en) * 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
WO2013012628A2 (en) * 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
JP2013094135A (ja) * 2011-11-02 2013-05-20 Waseda Univ 人工ナノ材料の安全性を評価する方法
CN103169968B (zh) * 2013-03-12 2014-11-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
WO2015040622A1 (en) * 2013-09-22 2015-03-26 Laster Brenda The continuous long-term controlled release of telomerase inhibitors
CN103933568B (zh) * 2014-05-12 2016-03-30 南京师范大学 一种水溶性竹红菌素plga纳米粒及其制备方法
US10456375B2 (en) 2014-09-30 2019-10-29 Biolitec Unternehmensbeteiligungs Ii Ag Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
WO2017019792A1 (en) * 2015-07-27 2017-02-02 The Texas A&M University System Surface active nanosystems
CN105343878B (zh) * 2015-11-30 2018-10-19 中国人民解放军第三军医大学第三附属医院 还原敏感型水溶性分子靶向光敏剂及其制备方法和应用
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
CN109481418B (zh) * 2017-12-19 2022-08-19 深圳先进技术研究院 抗肿瘤纳米颗粒及其制备方法和应用
EP3626268A1 (en) 2018-09-24 2020-03-25 Westfälische Wilhelms-Universität Münster Polymer-particle light-cleavable carrier systems for photodynamic therapy
EP3894421A1 (en) 2018-12-10 2021-10-20 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
WO2020185658A1 (en) * 2019-03-08 2020-09-17 North Carolina State University Photothermal therapy promotes tumor infiltration and antitumor activity of cart t cells
WO2022216927A1 (en) * 2021-04-07 2022-10-13 North Carolina State University Porphyrin-hydroporphyrin compounds, compositions comprising the same and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3372558B2 (ja) * 1990-09-14 2003-02-04 中外製薬株式会社 マイクロカプセル型徐放性製剤及びその製造法
JPH11514986A (ja) 1995-09-21 1999-12-21 ノバルティス アクチエンゲゼルシャフト 光力学的療法におけるナノ粒子
JP3765338B2 (ja) * 1995-12-15 2006-04-12 武田薬品工業株式会社 注射用徐放性製剤の製造法
US5829448A (en) * 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
GB0001455D0 (en) * 2000-01-21 2000-03-15 Scotia Holdings Plc Porphyrins and related compounds
WO2003092585A2 (en) * 2002-05-02 2003-11-13 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US7455858B2 (en) * 2002-05-16 2008-11-25 Qlt Inc. Compositions and methods for delivery of photosensitive drugs
EP1583473A2 (en) 2003-01-16 2005-10-12 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US20090304803A1 (en) * 2005-06-06 2009-12-10 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
熊小强 等: ""PLGA-m-THPC纳米型光敏剂的制备及其光动力治疗肝癌细胞的研究"", 《中华普通外科学文献（电子版）》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111000804A (zh) * 2019-12-05 2020-04-14 东南大学 一种甘露糖靶向的热响应铂纳米颗粒及其制备方法和应用
CN111000804B (zh) * 2019-12-05 2022-02-11 东南大学 一种甘露糖靶向的热响应铂纳米颗粒及其制备方法和应用

Also Published As

Publication number Publication date
JP2013513610A (ja) 2013-04-22
EP2509633A4 (en) 2015-08-26
CN102740892A (zh) 2012-10-17
BR112012013951A2 (pt) 2018-06-05
CA2784005C (en) 2018-01-02
WO2011071970A3 (en) 2011-11-17
EP2509633B1 (en) 2025-06-18
WO2011071970A2 (en) 2011-06-16
CA2784005A1 (en) 2011-06-16
EP2509633C0 (en) 2025-06-18
US20110275686A1 (en) 2011-11-10
JP5868869B2 (ja) 2016-02-24
EP2509633A2 (en) 2012-10-17

Similar Documents

Publication Publication Date Title
CN106913533A (zh) 基于聚(dl‑乳酸‑乙醇酸共聚物)的用于光动力疗法的纳米粒子载体系统
Camerin et al. The in vivo efficacy of phthalocyanine–nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma
Palanikumar et al. pH-responsive upconversion mesoporous silica nanospheres for combined multimodal diagnostic imaging and targeted photodynamic and photothermal cancer therapy
CN102740875A (zh) 基于人血清白蛋白的用于光动力疗法的纳米粒子载体系统
AU2004207813B8 (en) Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
Fadel et al. Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice
CN104162171B (zh) 一种包含二氢卟吩e6的多聚体白蛋白纳米球及其制备方法和应用
Moret et al. Folate-targeted PEGylated liposomes improve the selectivity of PDT with meta-tetra (hydroxyphenyl)-chlorin (m-THPC)
Zhang et al. Construction and in vitro and in vivo evaluation of folic acid-modified nanostructured lipid carriers loaded with paclitaxel and chlorin e6
Vargas et al. In vivo photodynamic activity of photosensitizer-loaded nanoparticles: formulation properties, administration parameters and biological issues involved in PDT outcome
Bœuf-Muraille et al. Evaluation of mTHPC-loaded PLGA nanoparticles for in vitro photodynamic therapy on C6 glioma cell line
Leandro et al. Evaluation of theranostic nanocarriers for near-infrared imaging and photodynamic therapy on human prostate cancer cells
Madani et al. Preparation of Methotrexate loaded PLGA nanoparticles coated with PVA and Poloxamer188
Park et al. Development of DH-I-180-3 loaded lipid nanoparticle for photodynamic therapy
da Silva et al. In vitro photodynamic activity of chloro (5, 10, 15, 20-tetraphenylporphyrinato) indium (III) loaded-poly (lactide-co-glycolide) nanoparticles in LNCaP prostate tumour cells
CN101850118B (zh) 加载于无机盐载体的脂溶性光敏剂的制备方法及其在制备光动力疗法药物中的应用
CN102949346B (zh) 蛋白载药纳米粒子的合成方法
Torres Martínez Molecular nanogels as nanocarriers. Intracellular transport of photosensitizers and nitric oxide probes
Gu Biodegradable porous silicon nanomaterials for imaging and treatment of cancer
Taratula et al. TaratulaOlehPharmacyNaphthalocyanine-Based. pdf
PAUL Photophysical investigation and pharmaceutical applications of chlorin e6 in biodegradable carriers
HK1088242B (en) Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170704

RJ01 Rejection of invention patent application after publication